- Home
- YOSH vs AYTU Comparison
YOSH vs AYTU Comparison
Compare YOSH & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOSH
- AYTU
- Stock Information
- Founded
- YOSH 2016
- AYTU N/A
- Country
- YOSH United States
- AYTU United States
- Employees
- YOSH N/A
- AYTU N/A
- Industry
- YOSH Restaurants
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- YOSH Consumer Discretionary
- AYTU Health Care
- Exchange
- YOSH Nasdaq
- AYTU Nasdaq
- Market Cap
- YOSH 23.7M
- AYTU 19.7M
- IPO Year
- YOSH 2022
- AYTU N/A
- Fundamental
- Price
- YOSH $1.65
- AYTU $2.23
- Analyst Decision
- YOSH
- AYTU Strong Buy
- Analyst Count
- YOSH 0
- AYTU 2
- Target Price
- YOSH N/A
- AYTU $10.00
- AVG Volume (30 Days)
- YOSH 671.4K
- AYTU 140.9K
- Earning Date
- YOSH 08-26-2025
- AYTU 09-25-2025
- Dividend Yield
- YOSH N/A
- AYTU N/A
- EPS Growth
- YOSH N/A
- AYTU N/A
- EPS
- YOSH N/A
- AYTU N/A
- Revenue
- YOSH $13,539,317.00
- AYTU $81,659,000.00
- Revenue This Year
- YOSH N/A
- AYTU N/A
- Revenue Next Year
- YOSH N/A
- AYTU $1.05
- P/E Ratio
- YOSH N/A
- AYTU $12.10
- Revenue Growth
- YOSH 41.82
- AYTU 0.41
- 52 Week Low
- YOSH $0.68
- AYTU $0.95
- 52 Week High
- YOSH $5.63
- AYTU $2.85
- Technical
- Relative Strength Index (RSI)
- YOSH 34.96
- AYTU 42.74
- Support Level
- YOSH $1.57
- AYTU $2.15
- Resistance Level
- YOSH $2.48
- AYTU $2.35
- Average True Range (ATR)
- YOSH 0.22
- AYTU 0.15
- MACD
- YOSH -0.00
- AYTU -0.05
- Stochastic Oscillator
- YOSH 9.89
- AYTU 8.96
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.